FY2024 EPS Estimates for GH Research Cut by HC Wainwright

GH Research PLC (NASDAQ:GHRS - Free Report) - Research analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for shares of GH Research in a research note issued on Tuesday, November 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.76) per share for the year, down from their prior forecast of ($0.75). HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for GH Research's current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for GH Research's Q1 2025 earnings at ($0.22) EPS, Q3 2025 earnings at $0.22 EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.88) EPS, FY2026 earnings at ($1.10) EPS and FY2027 earnings at ($1.18) EPS.

GHRS has been the topic of a number of other research reports. Canaccord Genuity Group decreased their target price on shares of GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a report on Monday. JMP Securities reiterated a "market outperform" rating and issued a $39.00 price objective on shares of GH Research in a research report on Wednesday, September 4th.

GH Research Price Performance

GHRS stock traded down $0.16 during mid-day trading on Friday, reaching $9.46. 56,236 shares of the company traded hands, compared to its average volume of 79,760. GH Research has a 52-week low of $5.05 and a 52-week high of $14.99. The company has a market capitalization of $492.20 million, a P/E ratio of -11.56 and a beta of 0.74. The company has a fifty day moving average price of $7.90 and a 200-day moving average price of $10.33.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.03.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. lifted its position in GH Research PLC (NASDAQ:GHRS - Free Report) by 1.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 6,686,689 shares of the company's stock after purchasing an additional 85,000 shares during the period. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 56.90% of the company's stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).